ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the mechanism of
methodsFifty SD rats were randomly divided into normal control group, CSD model group, and low-, medium-, and high-dose WYD treatment groups (
resultsCSD induced significant cognitive impairment and neuronal and synaptic damage in the rat models, causing also increased oxidative stress and iron deposition and upregulated Nrf2 and HO-1 expressions. Treatment with WYD, especially at the medium dose, significantly improved learning and memory abilities of the rat models, alleviated neuronal degeneration, restored synaptic structure, reduced iron accumulation and oxidative stress, and upregulated ferroptosis-related markers as well as Nrf2 and HO-1 expressions.
conclusionsWYD, optimally at the medium dose, alleviates CSD-induced cognitive impairment in rats by inhibiting ferroptosis, reducing neuronal damage, and enhancing synaptic repair via activation of the Nrf2/HO-1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.